Pro-inflammatory cytokine (IL-6) and total count lymphocyte profiles in COVID-19 patients with different severity levels by Permata Sari, Shinta Dewi et al.
J Med Sci, Volume 53, Number 3, 2021 July: 218-225
218*corresponding author: shinta.dps@uhamka.ac.id
Journal of the Medical Sciences
(Berkala Ilmu Kedokteran)










Pro-inflammatory cytokine (IL-6) and total count 
lymphocyte profiles in COVID-19 patients with different 
severity levels
Shinta Dewi Permata Sari1*, Wening Tri Mawanti1,2, Dewi Martalena1,2, Erlin Listiyaningsih1, 
Rizkyana Avissa1, Rini Latifah1,3, Wawang S Sukarya1
1Faculty of Medicine, Universitas Muhammadiyah Prof. DR. HAMKA, Jakarta, 2Jakarta Islamic 
Hospital, Pondok Kopi, Jakarta, 3Dr. M Goenawan Partowidigdo Pulmonary Hospital, Bogor, 
Indonesia
ABSTRACT
COVID-19 is caused by the SARS-CoV-2 infection that attacked the human 
respiratory system. In severe conditions, it causes pneumonia, kidney 
failure, acute respiratory distress syndrome (ARDS), and even death. The 
SARS-CoV-2 infection triggers the immune cells to secrete an excess of pro-
inflammatory cytokines lead to cytokine storm. It is believed to become one of 
the mechanisms that cause the ARDS condition. The level of pro-inflammatory 
cytokines will differ with each case severity. This study aimed to evaluate the 
profile of pro-inflammatory cytokines in COVID-19 patients with different 
severity. Therefore, it could be used as therapeutic approach for cytokine storm 
conditions. It was a cross sectional study using plasma samples of COVID-19 
patients from Jakarta Islamic Hospital, Pondok Kopi and Dr. M. Goenawan 
Partowidigdo Hospital, Cisarua, Indonesia. The COVID-19 patients with severe 
(n=20) and mild to moderate (n=25) severity were involved in this study. As 
negative control plasma sample from healthy subjects (n=13) was used. Plasma 
IL-6 levels were measured using the ELISA technique and plasma lymphocyte 
levels were measured using a hematology analyzer. The results showed that 
no significant difference between severity and gender was observed (p=0.256). 
Meanwhile, there is a significant difference in IL-6 level between negative 
control, mild-moderate, and severe categories (p=0.015). The average IL-6 
level in severe categories was higher than mild-moderate and negative control 
categories, with values 105.375, 59.75, and 64.577 pg/mL, respectively. This 
result becomes supporting evidence that there is a cytokine storm condition 
in severe COVID-19 patients. Furthermore, the lymphocyte level in the severe 
group is significantly lower than the mild to moderate group. This result may 
indicate lymphocytopenia in the severe group.
ABSTRAK
COVID-19 disebabkan oleh virus SARS-CoV-2 yang menyerang sistem 
pernapasan manusia. Pada kasus berat, COVID-19 menyebabkan pneumonia, 
gagal ginjal, acute respiratory distress syndrome (ARDS), bahkan kematian. 
Infeksi virus SARS-CoV-2 memicu sel imun mengsekresikan sitokin pro-
inflamasi dalam jumlah berlebihan yang disebut sebagai badai sitokin.  Hal 
ini dipercaya menjadi salah satu mekanisme penyebab terjadinya ARDS. 
Kadar sitokin pro-inflamasi akan berbeda pada setiap tingkat keparahan. 
Penelitian ini bertujuan untuk menentukan profil sitokin pro-inflamasi pada 
pasien COVID-19 dengan tingkat keparahan yang berbeda-beda, sehingga hasil 
tersebut dapat digunakan sebagai pendekatan terapi untuk mengatasi kondisi 
badai sitokin. Penelitian ini adalah penelitian potong lintang menggunakan 
sampel plasma pasien COVID-19 dari RSIJ Pondok Kopi dan RS Paru Dr. 
Goenawan Partowidigdo, Cisarua, Indonesia. Pasien COVID-19 dengan 
kelompok keparahan berat (n=20) dan ringan hingga sedang (n=25) 
dilibatkan dalam penelitian. Sebagai kontrol negatif digunakan 
subjek sehat sebanyak 13 sampel. Pengukuran kadar IL-6 plasma 
menggunakan teknik ELISA dan kadar limfosit plasma menggunakan 
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hematologi analyzer. Hasil penelitian menunjukkan tidak ada 
perbedaan signifikan antara tingkat keparahan dan jenis kelamin (p 
= 0,256). Namun demikian, terdapat perbedaan signifikan kadar IL-
6  antara kelompok kontrol negatif, ringan hingga sedang, dan berat 
(p=0,015). Rerata kadar IL-6 kelompok berat lebih tinggi dibandingkan 
kelompok kontrol negatif dan ringan hingga sedang, dengan nilai 
masing-masing sebesar 105,375, 59,750, dan 64,577 pg/mL. Hasil 
penelitian dapat mendukung adanya badai sitokin pada kelompok 
berat kasus COVID-19. Selain itu, kadar limfosit pada kelompok berat 
secara signifikan lebih rendah dibandingkan kelompok ringan hingga 
sedang. Hasil tersebut mungkin menunjukkan adanya limfositopenia 




Corona virus disease-19 (COVID-19) 
is caused by the severe acute respiratory 
syndrome Corona virus – 2 (SARS-
CoV-2) infection that attacks the human 
respiratory system. The SARS-CoV-2 has 
been initially transmitted from animals 
to humans. Then human-to-human 
transmission occurred through droplets, 
direct contact, or contaminated objects.1 
The first case of COVID-19 was reported 
on December 31, 2020, in Wuhan, 
China. Furthermore, the number of 
cases increased significantly and spread 
to various countries in a short time, 
including Indonesia. In March 2020, 
WHO declared the COVID-19 outbreak as 
a pandemic. As of March 2021, it has been 
one year after the first cases in Indonesia 
declared, the total number of confirmed 
cases in Indonesia was 1.379.662, with 
37.266 total deaths and 1.194.656 total of 
recovered patients.2 The rapid increase 
in COVID-19 cases may contribute to 
the possibility of transmission by the 
asymptomatic carrier.
Clinical manifestations of COVID-19 
usually appear within two days to 14 
days after exposure to the virus. Common 
signs and symptoms in mild cases include 
acute respiratory symptoms such as 
fever, cough, and shortness of breath. 
Severe cases can cause pneumonia, acute 
respiratory distress syndrome (ARDS), 
kidney failure, and even death.3 There 
were four classifications of COVID-19 
severity, such as asymptomatic (without 
symptoms), mild, moderate, and severe. 
The patient that experienced the 
asymptomatic phase does not feel any 
symptoms and sign physically. When 
the acute respiratory symptoms and 
systemic malaise appear, the viral load 
will increase significantly, thus classified 
as a mild phase. Furthermore, in the 
moderate phase, the disease progresses 
from the upper respiratory system 
to the lower respiratory system and 
becomes a pneumonia infection.4,5 The 
clinical symptoms in this phase include 
shortness of breath, use of nasal oxygen, 
and pneumonia thorax profile.
In the mild and moderate phases of 
COVID-19, an adaptive immune response 
is triggered to eliminate the virus and 
prevent progression to a severe clinical 
stage. Most of the patients experienced 
gradual recovery in their health 
conditions. However, if the response 
is maladaptive, it will progress to the 
severe condition causing damage to the 
tissue that expresses ACE2. The cellular 
mechanism internalization of SARS-CoV-2 
into the lung is by binding to the ACE2 
receptor in the surface of lung epithelial 
cells, subsequently, the virus replicates 
rapidly. This condition caused massive 
death of endothelial and epithelial cells, 
also triggered the massive production 
of pro-inflammatory cytokine.6 In 
the severe phase, the innate immune 
response could not resist the viral load. 
Therefore, some patients experience a 
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cytokine storm with increased levels of 
pro-inflammatory cytokines and other 
markers of inflammation, lymphopenia, 
and progressive respiratory failure.7 This 
condition can progress to a severe phase 
and occur in ARDS and multi-organ 
failure. Some studies have found that 
the ARDS condition is closely related to 
pro-inflammatory cytokine (IL-6, TNF-α, 
IL-1) and genetic susceptibility).4–6 Pro-
inflammatory cytokines are signaling 
molecules secreted by immune cells 
(T cells and macrophages) and other 
cells that promote inflammation and 
immunity.
Profiling IL-6 in COVID-19 patients 
was our early study to know the level 
of pro-inflammatory cytokine among 
other cytokines related to different 
severity of COVID-19. Further study 
related to another pro-inflammatory 
cytokine level should be conducted to 
determine which cytokine will increase 
significantly during the infection of the 
SARS-CoV-2. Some studies also reported 
that cytokine storm-related to decreased 
lymphocyte level in COVID-19 patients. 
Another study needs to be performed 
to profiling the other pro-and anti-
inflammatory cytokines in COVID-19 
patients with different severity to be 
used as a therapeutic approach for drug 
development.
MATERIALS AND METHODS
Study design and subjects
This was a cross-sectional study 
using blood samples from COVID-19 
patients collected from COVID-19 patients 
in Jakarta Islamic Hospital, Pondok 
Kopi, Jakarta and DR. M. Goenawan 
Partowidigdo Hospital, Cisarua, Bogor 
with different severity. The severity level 
of COVID-19 patients were categorized 
as mild to moderate and severe. The 
COVID-19 patients were considered mild 
if the patient confirmed COVID-19 with 
upper respiratory infection symptoms 
such as cough, nausea, fatigue, and fever, 
with or without anosmia. The COVID-19 
patients were considered moderate if 
the patient confirmed COVID-19 with 
upper respiratory infection symptoms, 
shortness of breath, used nasal oxygen 
as breathing support, and pneumonia 
thorax profile.  The COVID-19 patients 
were considered sever if the patient 
confirmed COVID-19 with lower 
respiratory infection, shortness of 
breath, ventilator as breathing support, 
and pneumonia thorax profile. The 
people confirmed COVID-19 who not 
hospitalized were excluded from 
this study. The healthy subjects were 
used as negative. The protocol of this 
study was approved by the Research 
Ethic Committee of University of 
Muhammadiyah Prof. DR. HAMKA, 
Jakarta. There was no conflict of interest 
in this study.
Assessment of plasma IL-6 level
Blood samples were taken, 
centrifuged at 1372 x g for 10 min and 
the plasma was separated. Plasma 
samples were then stored at -80°C until 
analysis. the measurement of IL-6. 
Plasma IL-6 levels were measured with 
the ELISA technique. This technique 
was chosen based on literature that uses 
the ELISA technique in measuring the 
anti and/or pro-inflammatory cytokines 
in plasma.8–10 The measurement 
procedure was carried out by the 
ELISA Kit (Elabscience). Measurements 
using the ELISA technique are based 
on specific reactions between antigens 
and antibodies with high sensitivity and 
specificity, using enzymes as indicators 
to generate a detectable signal. The 
specific antibody will bind to the 
antigen, and then the enzyme causes a 
color change of the solution through an 
enzymatic reaction. The results were 
obtained quantitatively by observed 
optical density (OD) value from the color 
intensity of the solution measured by an 
ELISA reader and read as absorbance 
value. The standard curve was used to 
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calculate the concentration of samples 
by inputting the absorbance sample 
into the linear regression equation of 
standard curve lines.
Total count lymphocyte in plasma
The data of lymphocyte level was 
collected from medical record data 
COVID-19 patients in Jakarta Islamic 
Hospital, Pondok Kopi, Jakarta and 
DR. M. Goenawan Partowidigdo 
Hospital, Cisarua. The measurement of 
lymphocytes was carried out using a 
hematology analyzer.
Statistical analysis
The plasma IL-6 levels were 
compared among different severity 
and analyzed statistically by IBM SPSS-
12 software using the chi-square test. 
The statistical significance was shown 
as p<005. The total count lymphocyte 
profile was analyzed statistically by t-test 
methods. The correlation study between 
gender and severity, age and severity, 
IL-6 levels and severity, lymphocyte 
level, and severity were analyzed using 
Pearson correlation analysis.
RESULTS
Characteristics of patients 
Thirteen healthy subjects and forty-
five COVID-19 patients consisted of mild 
to moderate cases (25 patients) and 
severe cases (20 patients) were involved 
in this study.  The general characteristics 
of patients are shown in TABLE 1. The 
age range of the subject in this study is 
approximately 19 – 73 y.o. The gender 
ratio between males and females was 
3:2. The average age of subjects in the 
negative control, mild to moderate, 
and severe groups were 29, 43, and 50 
y.o., respectively. Normality tests by 
Kolmogorov Smirnov methods showed 
that data gender was not normally 
distributed (p<0.05). Comparative 
analysis between studied groups was 
conducted by chi-square methods. 
There was no significant difference 
between severity and gender (p=0.256). 
Meanwhile, another result related to the 
correlation between age and severity 
showed a positive correlation based on 
the Pearson correlation analysis (r count 
> r table) as shown in TABLE 2.






Age (median y.o.) 29 (28) 43 (42) 50 (49)
Sex (n)
•	 Male 7 13 14
•	 Female 6 12 6
TABLE 2. Correlation between age and severity
Parameters Mean SD n r count r table p
Age 42.214 14.509 56 0.534 0.263 0.00
Group 2.11 0.755 56 0.534 0.263 0.00
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IL-6 and lymphocyte levels
FIGURE 1 shows the distribution of 
plasma IL-6 levels in the three groups. 
The plasma IL-6 levels among the three 
groups were not normally distributed. 
The median plasma IL-6 levels in the 
severe group (96.5 pg/mL) were higher 
than the negative control (61.5 pg/mL) 
and mild to moderate group (59.0 pg/mL). 
The analysis result showed a statistical 
difference between plasma IL-6 levels in 
mild to moderate group compared to the 
severe group (p<0.05).
FIGURE 1. Distribution of plasma IL-6 level (pg/mL) in the 
negative control, mild to moderate, and severe 
categories
The lymphocyte level results showed 
a normal distribution (p>0.05) and 
conducted a t-test analysis. The statistical 
analysis result showed a significant 
difference in lymphocyte level between 
the severe and mild to moderate groups 
(p=0.015). Average lymphocyte levels 
in the severe group were lower than 
the mild to moderate group (FIGURE 2) 
with 16.40% and 24.70%. The Pearson 
correlation was conducted among the 
two groups and showed no correlation 
between IL-6 and lymphocyte level. 
Meanwhile, IL-6 level and lymphocyte 
level may correlate to the severity of the 
disease.
FIGURE 2. Level of lymphocytes in the mild to moderate 
and severe group. Value levels are shown 
as mean. Significant differences were 
performed by *p < 0.05.
*
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DISCUSSION
This study showed the profile 
of plasma IL-6 as a cytokine pro-
inflammatory and lymphocyte of 
COVID-19 patients with different 
severity. In general, the characteristics of 
patients showed no differences between 
severity and gender. The women and 
men patients have the same potency 
to undergo mild to moderate or severe 
in the COVID-19 cases. de Brito et al.11 
studies showed the same result regarding 
the differences between severity and 
gender in COVID-19 patients. The data 
also showed the varied ages in each 
group severity of COVID-19 and showed 
the positive correlation between age 
and severity. This finding considered 
that the older age has a higher risk of 
experiencing COVID-19 and progression 
of the disease. However, it is also 
important to consider other factors 
that could elevate the risk of COVID-19. 
Marlin et al.12 also reported that older age 
is associated with mortality and severity 
of the disease. Many factors are related 
to the severity of COVID-19, including 
demographic, comorbidity, alcohol, and 
smoking. Therefore, another study with 
more comprehensible risk factors should 
be conducted.
The severity of COVID-19 is also 
related to immune response, including 
pro-and anti-inflammatory cytokine. 
An excessive secretion of cytokine 
proinflammatory is associated with 
severe conditions of COVID-19 patients 
and could trigger the ARDS condition 
and multi-organ failure.7 This study has 
shown elevated IL-6 levels in the severe 
group than the mild to moderate group. 
A sample in the severe group showed 
the highest level of IL-6 then the patient 
undergoes a worsening condition. These 
findings are considered the evidence 
for the presence of cytokine storms in 
severe conditions. de Brito et al.11 and 
Zhang et al.13 also reported the elevated 
IL-6 levels in the severe group. The 
presence of pro-inflammatory cytokines 
triggered another immune response to 
increased secretion of anti-inflammatory 
cytokines (IL-10, IL-4, IL-13) by T cells 
or macrophages. Therefore, further 
analysis regarding the ratio of pro-and 
anti-inflammatory cytokines needs to be 
performed to estimate the possibility of 
the ARDS condition.
Anti-inflammatory cytokines play 
a role in suppressing inflammatory 
and neoplastic processes by inhibiting 
IFN-γ production and activating 
specific antigen T cells. The balance 
of plasma level between pro-and anti-
inflammatory cytokines can affect the 
degree of inflammation and, in severe 
conditions, may prevent the progression 
of the disease.14 Therefore, the elevated 
IL-6 levels should be followed by a high 
level of anti-inflammatory cytokines, 
as the body may be able to cope with 
the cytokine storm, thereby reduce the 
risk of worsening condition and ARDS. 
As one example from the severe group, 
there was a highest IL-6 level (220 pg/mL) 
among the others group and experienced 
progression of the disease and even 
death. However, other factors such as 
physiological conditions or comorbidity 
can also cause worsening of the patient’s 
condition.
The occurrence of systemic 
inflammatory conditions or cytokine 
storms in the severe group is also related 
to lymphocytopenia.15 Jafarzadeh et 
al16 studies showed the level of blood 
lymphocytes has manifested the most 
significant and reliable correlation with 
the disease progression and severity in 
COVID-19 patients and considered as an 
accurate indicator for the classification 
of COVID-19 patients in moderate, 
severe, and critical cases. This study 
showed decreased lymphocyte level in 
the severe group compared to the mild 
– moderate group. Chen et al.17 studies 
also showed a decrease in lymphocyte 
levels in the severe group compared 
to the mild-moderate group. Some 
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mechanisms may be underlying the 
decrease of lymphocytes in the severe 
group of COVID-19, such as apoptosis 
lymphocytes induced by SARS-CoV-2 
infection, SARS-CoV-2 infection mediated 
thymus suppression, and the occurrence 
of cytokine storm that could induce the 
apoptosis of lymphocyte.16 Therefore, 
another study should be performed 
to understanding the mechanism of 
lymphocytopenia in COVID-19 cases.
CONCLUSION
There is no correlation between 
gender and severity of COVID-19, 
otherwise a significant difference 
between age and severity of COVID-19 is 
observed. The plasma IL-6 levels in the 
severe group are higher than the mild-
moderate group. It can be concluded 
that the COVID-19 patients in the severe 
group potentially undergo the cytokine 
storm condition that could lead to the 
progression of the disease. Furthermore, 
the severity of COVID-19 related to low 
lymphocyte level and lymphocytopenia 
may cause serious effects in the severe 
group. Lymphocyte level in the severe 
group is significantly lower than the mild 
to moderate group. Further study related 
to lymphocytopenia in severe conditions 
should be performed to comprehend 
some possible mechanisms underlying 
this condition.
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